ImClone Investigational Site

Indianapolis, Indiana 46282

0 studies enrolling now · 8 studies all time

What they study most

Breast Cancer, Cancer, Carcinoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Metastases, Neoplasm, Neuroendocrine Tumors, Non-Small-Cell Lung Cancer, Ovarian Neoplasms, Solid Tumors

Studies at this site

• A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer — Completed
• A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer — Completed
• Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients — Completed
• Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy — Completed
• Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available — Completed
• Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy — Completed
• Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer — Completed
• Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer — Completed